Johnson & Johnson Unit Defeated In Oxybutynin Case; Mylan To Produce Generic Version
In a stinging defeat for Johnson & Johnson's Alza Corp., a federal court has ruled that Mylan's generic version of the overactive bladder treatment Ditropan XL does not infringe on Alza's...To view the full article, register now.
Already a subscriber? Click here to view full article